Il choose
the correct Answer.
[ X 1 = 14
а a
1/f = {0, a), (3, b), (4, b), (5,03 is.
2) idomlity function
b) one-one function
c)
many_ome function d) constant function.
2. If n(A) =P and
(a) Ptq
b) p-q
n (B) =q
them n(AXB) =
o Pxq
d) Pla
3. A = { a, b, p} B = {2,3} , C= {P, q r s} them n(AUC) X B] is
8
bloo
d) 16
4- The
range of the relation R = {(x, x2) 1 x is
prime number less than
13 } is
a) 2, 3, 5, 7} b){2, 3, 5, 7, 1} c) {4,9, 25, 49, 121} d) {1,4,9, 25, 1412}
5- If f(x) = 2x² and g(x)= 1/x Them
a) 3/2x² b) 2/3y2 c) 2/9x²
fog
is
d) 1/6x²
6. If
the
H.C.E of 65 and 17. is expressible
the form of 65m - 117, them the
is
b) I
c)2
da
value of
m
7 The sum
factors
of 음
im
the exponents of the
Prime
the Prime factonisation of 189 is
b)2
d) 4
la) 2
C) 3
Answers
Answer:
In December 2019, the 2019 novel coronavirus (2019-nCoV) was discovered and identified in the viral pneumonia cases that occurred in Wuhan, Hubei Province, China; And then was named by the World Health Organization (WHO) on 12 January 2020. In the following month, the 2019-nCoV quickly spreading inside and outside of Hubei Province and even other countries. What’s more, the sharp increase of the case number caused widespread panic among the people.
Medical professionals require an up-to-date guideline to follow when an urgent healthcare problem emerging. In response to the requests for reliable advice from frontline clinicians and public healthcare professionals managing 2019-nCoV pandemics, we developed this rapid advance guideline, involving disease epidemiology, etiology, diagnosis, treatment, nursing, and hospital infection control for clinicians, and also for public health workers and community residents.
2 Guideline methodology
This guideline was prepared in accordance with the methodology and general rules of WHO Guideline Development and the WHO Rapid Advice Guidelines [1, 2].
2.1 Composition of the guideline development group
This guideline development group is multidisciplinary and composed of individuals from health professionals and methodologists. Health professionals included frontline clinical doctors, nurses who work in departments of respiratory medicine, fever clinic, critical medicine, emergency, infectious disease, and experts of respiratory infectious disease and hospital management board. The methodologists included methodologists of guideline development, systematic review, and literature searching professionals.
2.2 The end-user of the guideline
This guideline is suitable for frontline doctors and nurses, managers of hospitals and healthcare sections, healthy community residents, personnel in public healthcare, relevant researchers, and all persons who are interested in the 2019-nCoV management.
2.3 The target population of the guideline
This guideline is aimed to serve the healthcare professionals to tackle the suspected 2019-nCoV infected cases, confirmed 2019-nCoV infected cases, clustered 2019-nCoV infected cases, and those with close contacts or suspicious exposure to 2019-nCoV infected cases.
2.4 A survey of conflict of interests
Oral inquiry for financial interests of relevant personal was conducted at the first meeting while to start this guideline. Relevant financial as well as nonfinancial interests were surveyed and disclosed and subsequently assessed in consensus conference in order to minimize potential bias in guideline development. Finally, there is no conflict of interests for all the personnel participating to prepare this guideline.
2.5 Guideline’s structural setup and refining the topics and coverage of this guideline
This guideline is a rapid guideline to responding to the emerging infectious disease of 2019-nCoV. Due to ”, “low quality”, or “very low quality”; Recommendations were classified as “strong” or “weak.”
The strong recommendation does not always mean there is sufficient